|
AUPS137402A0
(en)
|
2002-03-26 |
2002-05-09 |
Fujisawa Pharmaceutical Co., Ltd. |
Novel tricyclic compounds
|
|
US8404713B2
(en)
|
2007-10-26 |
2013-03-26 |
Janssen Pharmaceutica Nv |
Quinolinone derivatives as PARP inhibitors
|
|
BRPI0820701A2
(pt)
|
2007-12-11 |
2015-06-16 |
Cytopathfinder Inc |
Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
|
|
CN102341394B
(zh)
|
2009-01-23 |
2015-04-15 |
武田药品工业株式会社 |
聚(adp-核糖)聚合酶(parp)抑制剂
|
|
EP2459561A1
(en)
|
2009-07-30 |
2012-06-06 |
Takeda Pharmaceutical Company Limited |
Poly (adp-ribose) polymerase (parp) inhibitors
|
|
US20110071136A1
(en)
|
2009-09-16 |
2011-03-24 |
Cylene Pharmaceuticals, Inc |
Novel tricyclic protein kinase modulators
|
|
PL2912032T3
(pl)
|
2012-10-26 |
2020-11-16 |
Nerviano Medical Sciences S.R.L. |
Pochodne 4-karboksyamido-izoindolinonu jako selektywne inhibitory parp-1
|
|
CN104370898A
(zh)
|
2013-08-14 |
2015-02-25 |
黄传满 |
咪唑并[1,2-a]吡啶类化合物及其制备方法和用途
|
|
CA2941716A1
(en)
|
2014-03-07 |
2015-09-11 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
|
CN105753814A
(zh)
|
2015-01-01 |
2016-07-13 |
成都贝斯凯瑞生物科技有限公司 |
取代氮杂环衍生物及其应用
|
|
MX375707B
(es)
|
2015-06-09 |
2025-03-06 |
Onconic Therapeutics Inc |
Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
|
|
CR20180168A
(es)
|
2015-08-17 |
2018-06-27 |
Lupin Ltd |
Derivados de heteroarilo como inhibidores de parp
|
|
AU2018273356B2
(en)
|
2017-05-22 |
2021-09-16 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
IL283127B1
(en)
|
2018-11-14 |
2026-02-01 |
Smilebiotek Zhuhai Ltd |
Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders
|
|
SI3999506T1
(sl)
|
2019-07-19 |
2025-06-30 |
Astrazeneca Ab |
Zaviralci PARP1
|
|
US12459899B2
(en)
|
2019-10-30 |
2025-11-04 |
DIGMBIO, Inc. |
Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient
|
|
US11795158B2
(en)
|
2020-06-25 |
2023-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
US11591331B2
(en)
|
2021-04-19 |
2023-02-28 |
Xinthera, Inc. |
PARP1 inhibitors and uses thereof
|
|
EP4328224A4
(en)
|
2021-04-22 |
2025-06-18 |
Wigen Biomedicine Technology (Shanghai) Co., Ltd. |
PARP INHIBITOR WITH PIPERAZINE STRUCTURE, MANUFACTURING METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
|
|
AU2022261029A1
(en)
|
2021-04-23 |
2023-10-19 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Heterocyclic derivative inhibitor and preparation method therefor and application thereof
|
|
WO2022222965A1
(zh)
|
2021-04-23 |
2022-10-27 |
成都百裕制药股份有限公司 |
吡啶衍生物及其在医药上的应用
|
|
WO2022222966A1
(zh)
|
2021-04-23 |
2022-10-27 |
成都百裕制药股份有限公司 |
一种选择性parp1抑制剂及其应用
|
|
CN115702156A
(zh)
|
2021-04-23 |
2023-02-14 |
南京明德新药研发有限公司 |
吡啶酰胺类化合物
|
|
WO2022228387A1
(en)
|
2021-04-26 |
2022-11-03 |
Fochon Biosciences, Ltd. |
Compounds as parp inhibitors
|
|
BR112023022496A2
(pt)
|
2021-05-24 |
2024-01-16 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos
|
|
CN115403595A
(zh)
|
2021-05-27 |
2022-11-29 |
江苏恒瑞医药股份有限公司 |
含氮杂环类化合物、其制备方法及其在医药上的应用
|
|
BR112023024942A2
(pt)
|
2021-06-16 |
2024-02-15 |
Repare Therapeutics Inc |
Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer
|
|
AU2022334408A1
(en)
*
|
2021-08-27 |
2024-02-15 |
Impact Therapeutics (Shanghai), Inc. |
Substituted tricyclic compounds as parp inhibitors and use thereof
|
|
CN118119618A
(zh)
|
2021-09-09 |
2024-05-31 |
南京奥利墨斯医药科技有限公司 |
一种杂芳环类化合物及其应用
|
|
WO2023046034A1
(zh)
|
2021-09-22 |
2023-03-30 |
明慧医药（杭州）有限公司 |
一种含氮杂环化合物、其制备方法、其中间体及其应用
|
|
WO2023046158A1
(zh)
|
2021-09-26 |
2023-03-30 |
张文燕 |
氮杂喹啉酮类化合物及其医药用途
|
|
WO2023046149A1
(zh)
|
2021-09-26 |
2023-03-30 |
张文燕 |
喹喔啉类化合物及其医药用途
|
|
EP4410792A4
(en)
|
2021-09-30 |
2025-12-03 |
Xizang Haisco Pharmaceutical Co Ltd |
NITROGEN-CONTAINS HETEROCYCLIC DERIVATIVE FOR USE AS A PARP INHIBITOR AND ITS USE
|
|
EP4410791A4
(en)
|
2021-09-30 |
2025-10-22 |
Xizang Haisco Pharmaceutical Co Ltd |
BICYCLIC DERIVATIVE PARP INHIBITOR AND ITS USE
|
|
WO2023051716A1
(zh)
|
2021-09-30 |
2023-04-06 |
海思科医药集团股份有限公司 |
杂芳基衍生物parp抑制剂及其用途
|
|
KR102867210B1
(ko)
|
2021-10-01 |
2025-10-14 |
신테라, 인크. |
아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도
|
|
WO2023061406A1
(zh)
|
2021-10-12 |
2023-04-20 |
微境生物医药科技(上海)有限公司 |
含三并环结构的parp抑制剂、及其制备方法和医药用途
|
|
US20250289800A1
(en)
|
2021-11-19 |
2025-09-18 |
Kangbaida (Sichuan) Biotechnology Co., Ltd. |
Selective Parp1 Inhibitor And Application Thereof
|
|
CN116143776A
(zh)
|
2021-11-22 |
2023-05-23 |
南京圣和药业股份有限公司 |
Parp1抑制剂及其应用
|
|
KR20240144125A
(ko)
|
2021-12-17 |
2024-10-02 |
키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 |
Parp 억제제, 이를 포함하는 약제학적 조성물, 및 이의 용도
|
|
WO2023133413A1
(en)
|
2022-01-07 |
2023-07-13 |
Slap Pharmaceuticals Llc |
Multicyclic compounds
|
|
KR20240134366A
(ko)
|
2022-01-13 |
2024-09-09 |
에이스랜드 테라퓨틱스 (홍콩) 리미티드 |
피페라진 고리 함유 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 용도
|
|
CN118434725B
(zh)
|
2022-01-20 |
2026-01-02 |
微境生物医药科技(上海)有限公司 |
吡啶酰胺类parp抑制剂、及其制备方法和医药用途
|
|
CN120081844A
(zh)
|
2022-01-21 |
2025-06-03 |
新特拉有限公司 |
Parp1抑制剂及其用途
|
|
CN116535401A
(zh)
|
2022-01-25 |
2023-08-04 |
南京圣和药业股份有限公司 |
新的parp1抑制剂及其应用
|
|
WO2023143236A1
(zh)
|
2022-01-26 |
2023-08-03 |
中国药科大学 |
2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
|
|
JP7794989B2
(ja)
|
2022-01-27 |
2026-01-06 |
シンセラ， インコーポレイテッド |
Ｐａｒｐ１阻害薬及びその使用
|
|
WO2023147009A1
(en)
|
2022-01-27 |
2023-08-03 |
The Johns Hopkins University |
Clinical-grade therapeutic progenitors generated from tankyrase/parp-inhibited pluripotent stem cell banks
|
|
KR20230116457A
(ko)
|
2022-01-28 |
2023-08-04 |
경북대학교 산학협력단 |
작약 추출물을 포함하는 만성폐쇄성폐질환 예방 또는 치료용 약학적 조성물
|
|
WO2023146960A1
(en)
|
2022-01-28 |
2023-08-03 |
Xinthera, Inc. |
Parp1 inhibitors and uses thereof
|
|
EP4469046A1
(en)
|
2022-01-28 |
2024-12-04 |
Oulun Yliopisto |
Compounds for use in the treatment of cancer and inflammatory conditions
|
|
IL314895A
(en)
|
2022-02-16 |
2024-10-01 |
Duke Street Bio Ltd |
Pharmaceutical compound
|
|
CN119013279A
(zh)
|
2022-03-11 |
2024-11-22 |
上海瑛派药业有限公司 |
作为parp抑制剂的取代的三环类化合物及其应用
|
|
CN119487027A
(zh)
|
2022-04-28 |
2025-02-18 |
宁波新湾科技发展有限公司 |
作为parp1抑制剂的化合物
|
|
AU2023259236B2
(en)
|
2022-04-28 |
2025-01-09 |
Xinthera, Inc. |
Tricyclic parp1 inhibitors and uses thereof
|
|
WO2023207284A1
(en)
|
2022-04-28 |
2023-11-02 |
Ningbo Newbay Technology Development Co., Ltd |
Piperazine derivatives as parp1 inhibitiors
|
|
JP7835895B2
(ja)
|
2022-05-07 |
2026-03-25 |
サイブランチ セラピューティクス カンパニー リミテッド |
Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体
|
|
EP4534537A4
(en)
|
2022-05-25 |
2025-12-10 |
Xizang Haisco Pharmaceutical Co Ltd |
BICYCLE-DERIVED PARP INHIBITOR AND ITS USE
|
|
US20250346573A1
(en)
|
2022-06-02 |
2025-11-13 |
Chengdu Easton Biopharmaceuticals Co., Ltd. |
Azaquinolinone derivative, preparation method therefor and use thereof
|
|
CN117447449A
(zh)
|
2022-07-13 |
2024-01-26 |
南京圣和药业股份有限公司 |
Parp1抑制剂及其应用
|
|
CN115232129B
(zh)
|
2022-08-18 |
2023-12-01 |
上海闻耐医药科技有限公司 |
一种parp1选择性抑制剂及其制备方法和用途
|
|
WO2024041643A1
(zh)
|
2022-08-25 |
2024-02-29 |
江苏恒瑞医药股份有限公司 |
稠合三环类化合物、其制备方法及其在医药上的应用
|
|
WO2024050370A1
(en)
|
2022-08-30 |
2024-03-07 |
1Cbio, Inc. |
Heterocyclic compounds and methods of use thereof
|
|
WO2024046420A1
(zh)
|
2022-08-31 |
2024-03-07 |
江苏恒瑞医药股份有限公司 |
稠合二环类化合物、其制备方法及其在医药上的应用
|
|
CN117658983A
(zh)
|
2022-09-01 |
2024-03-08 |
浙江文达医药科技有限公司 |
选择性parp1抑制剂
|
|
CN118119629A
(zh)
|
2022-09-30 |
2024-05-31 |
中国医药研究开发中心有限公司 |
含氮杂环类化合物及其医药用途
|
|
WO2024067694A1
(zh)
|
2022-09-30 |
2024-04-04 |
中国医药研究开发中心有限公司 |
含氮杂环类化合物及其医药用途
|
|
US20240174669A1
(en)
|
2022-10-06 |
2024-05-30 |
Xinthera, Inc. |
Crystalline forms of a parp1 inhibitor
|
|
WO2024083218A1
(zh)
|
2022-10-20 |
2024-04-25 |
成都赜灵生物医药科技有限公司 |
取代四氢吡啶类化合物及其用途
|
|
WO2024083211A1
(zh)
|
2022-10-20 |
2024-04-25 |
成都赜灵生物医药科技有限公司 |
并杂环类氘代化合物及其用途
|
|
CN117946074A
(zh)
|
2022-10-20 |
2024-04-30 |
上海海和药物研究开发股份有限公司 |
具有parp1抑制活性的化合物及其用途
|
|
WO2024083201A1
(zh)
|
2022-10-20 |
2024-04-25 |
成都赜灵生物医药科技有限公司 |
并杂环类化合物及其用途
|
|
CN120603832A
(zh)
|
2022-11-09 |
2025-09-05 |
来凯制药(宁波)有限公司 |
稠合多环化合物及其作为parp1抑制剂的用途
|
|
WO2024099416A1
(zh)
|
2022-11-10 |
2024-05-16 |
上海海和药物研究开发股份有限公司 |
一种稠合三环类parp1抑制剂、其制备方法及用途
|
|
CN120035596A
(zh)
|
2022-11-23 |
2025-05-23 |
江苏恒瑞医药股份有限公司 |
一种含氮杂环类化合物的可药用盐、晶型及制备方法
|
|
CN118084916A
(zh)
|
2022-11-25 |
2024-05-28 |
成都赜灵生物医药科技有限公司 |
三并杂环类化合物及其用途
|
|
WO2024206172A1
(en)
|
2023-03-24 |
2024-10-03 |
Xinthera, Inc. |
Crystalline forms of an azetidine parp1 inhibitor
|
|
CN116987066B
(zh)
|
2023-06-20 |
2025-07-25 |
四川大学 |
一种嘧啶类化合物及其制备方法和应用
|
|
CN117017962A
(zh)
|
2023-08-23 |
2023-11-10 |
复旦大学附属肿瘤医院 |
一种hdaci抑制剂在制备治疗卵巢癌药物中的用途
|